The company recently announced that preliminary analysis of safety data from a Phase III cardiac surgery study with Oxygent showed no evidence to link the product directly to an imbalance in certain adverse events that led to the voluntary suspension of enrollment in the study in January. The company did not release any news during the week to account for the gain. The stock declined even though the company reported continued progress towards establishing its HPV test as part of the standard of care for cervical cancer prevention in the United States. Given the biotech sector's volatility, it seems an ironic place to look for a safe haven. Such Information is neither an offer to sell nor a solicitation to buy the securities of any company.
Additional information is available upon request.
Information in this publication has been obtained from sources believed to be reliable, but the accuracy, completeness and interpretation are not guaranteed. Opinions expressed are subject to change without notice. BioSpace, and BioSpace's employees and officers, as well as Wayne Hummer Investments LLC, and Wayne Hummer Investments LLC 's employees and officers, in no way accept responsibility for any of the Newsletter's content. The Information is supplied on the condition that the reader or any other person receiving the Information will make his or her own determination as to its suitability for any purpose prior to any use of the Information. Also BioSpace, Inc. and Wayne Hummer Investments LLC may, from time to time solicit business from any company mentioned in this report.